New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are ...

Trump’s order to halt all international aid programs has left thousands of workers in limbo and millions of beneficiaries in ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

A 17-year-old teen was charged in connection to seven separate arsons that occurred between late November 2024 through January 2025.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.